Zyvox有效提高手术部位MRSA感染患者治疗成功率

根据2004年11月发表在《美国手术期刊》的报道，使用Zyvox治疗甲氧苯青霉素耐药金黄色葡萄球菌感染手术患者的成功率是87％，而使用万古霉素治疗成功率是48％。

手术部位感染患者有60％的可能在重症监护室度过，重新入院治疗的可能性增加了5倍，死亡可能增加了2倍。数据显示2000年MRSA导致了美国医院30％手术部位感染，而1997年只有24％。在该项研究中，大多数患者接受了静脉制剂的Zyvox。尽管总体治疗时间相似，但是患者使用Zybox静脉治疗平均时间显著少于万古霉素患者（4.7天vs11.1天）

The subset analysis of 135 patients with surgical site infections was taken from a large, randomized, multicenter trial of 1,200 patients designed to compare the clinical efficacy and safety of Zyvox (Pfizer, Inc.).
对一项比较Zyvox临床效能与安全性的大规模随机多中心临床试验1200例患者中的135例手术部位感染的患者进行了亚类分析。

威斯康星州外科副主任、教授、首席研究员John Weiglt教授说：“由于MRSA导致的手术部位感染的流行率不断增高，早期鉴别MRSA感染以及寻找万古霉素的替代药物的任务迫在眉睫，因为任何接受手术的患者都处于危险之中。”

Zyvox Best for MRSA Surgical Site Infections
 
Surgical patients treated for methicillin-resistant Staphylococcus aureus (MRSA) with Zyvox (linesolid) showed success rates of 87% compared to 48% for patients treated with vancomycin, according to a new study published in the December 2004 issue of the American Journal of Surgery.

Patients who develop surgical site infections are 60% more likely to spend time in an intensive care unit, five times more likely to be re-admitted to the hospital, and twice as likely to die. Data show that MRSA caused 30% of surgical site infections in U.S. hospitals in 2000, compared to 24% in 1997. In the study, most patients received the intravenous (IV) formulation of Zyvox. Although the total length of treatment among groups was comparable, the mean duration of IV treatment was significantly shorter for Zyvox patients than for vancomycin patients (4.7 days vs 11.1 days, respectively).

The subset analysis of 135 patients with surgical site infections was taken from a large, randomized, multicenter trial of 1,200 patients designed to compare the clinical efficacy and safety of Zyvox (Pfizer, Inc.).

“As the prevalence of surgical site infections caused by MRSA increases, identifying MRSA early and having alternatives to vancomycin become extremely important, since any patient undergoing surgery is at risk,” said lead investigator Dr. John Weigelt, professor and vice chairman of the department of surgery at the Medical College of Wisconsin (Milwaukee, USA).